Remicade infliximab regulatory update

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508, Osaka, Japan) said Japan's Ministry of Health, Labor and Welfare (MHLW) lifted the conditional approval of Remicade infliximab for psoriasis. The chimeric mAb against tumor necrosis factor (TNF) alpha received conditional approval for the indication in 2010. Mitsubishi Tanabe markets Remicade in Japan for rheumatoid arthritis (RA), active Crohn's disease, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis and ulcerative colitis. ...